8-K: AEON Biopharma Secures $15 Million Convertible Note Financing and Aligns with FDA on Migraine Program

AEON Biopharma has entered into a $15 million senior secured convertible note financing agreement with Daewoong Pharmaceutical and received FDA alignment on its Phase 3 migraine program.

Summary

• AEON Biopharma has secured a financing agreement with Daewoong Pharmaceutical for up to $15 million through senior secured convertible notes.
• The initial closing will provide $5 million, with a subsequent $10 million contingent on amending a prior license agreement and other conditions.
• The funds will support the late-stage clinical development of ABP-450 and general working capital.
• The convertible notes carry a 15.79% annual interest rate and mature in three years.
• The notes can convert to common stock under certain conditions, including a qualified financing of at least $30 million or positive Phase 3 clinical data.
• Daewoong will have the right to appoint a board member after the second closing.
• AEON will seek stockholder approval to remove conversion caps on the notes.
• The company also terminated forward purchase agreements with ACM ARRT J LLC and Polar Multi-Strategy Fund, retaining previously issued shares and facing potential liquidated damages up to $1.5 million each if registration requirements are not met.
• AEON had a productive end-of-Phase 2 meeting with the FDA, aligning on the design and endpoints for the proposed pivotal Phase 3 trials for the preventive treatment of both episodic and chronic migraine.
• An interim analysis from the ongoing Phase 2 study in chronic migraine will now be conducted and data are expected in Q2 2024.

Sentiment

Score: 7

Explanation: The document contains positive news regarding financing and FDA alignment, but also includes risks related to the financing terms and potential liabilities. The overall sentiment is positive but tempered by the challenges ahead.

Positives

• The $15 million financing provides crucial capital for the development of ABP-450.
• The FDA alignment on Phase 3 trial design reduces regulatory risk.
• The interim analysis of the Phase 2 chronic migraine study could provide positive data sooner than expected.
• The termination of forward purchase agreements simplifies the capital structure.

Negatives

• The convertible notes have a high interest rate of 15.79%.
• The company faces potential liquidated damages of up to $3 million if registration requirements are not met.
• The conversion of the notes is subject to certain conditions, including a qualified financing or positive clinical data.
• The license agreement with Daewoong can be terminated if AEON ceases to commercialize or advance clinical studies of ABP-450 in certain territories.

Risks

• The company's ability to raise additional financing in the future is uncertain.
• The company may not be able to meet the conditions for conversion of the notes.
• The company may not be able to obtain stockholder approval to remove the conversion cap.
• The company may not be able to meet the registration requirements for the retained shares from the terminated forward purchase agreements.
• The company's clinical trials may not be successful.
• The company may face competition from other companies developing treatments for migraine.

Future Outlook

AEON plans to use the proceeds from the financing to support the late-stage clinical development of ABP-450 and for general working capital purposes. The company will also seek stockholder approval to remove conversion caps on the notes and file a shelf registration statement to register the resale of shares issuable upon conversion of the notes. The company will conduct an interim analysis of the ongoing Phase 2 study of ABP-450 for the preventive treatment of chronic migraine and anticipates releasing the data in the second quarter of 2024.

Management Comments

• We are pleased to announce a productive end-of-Phase 2 meeting with the FDA, during which we aligned on the proposed study design and the primary endpoint for the pivotal Phase 3 program with ABP-450 injection for the preventive treatment of episodic and chronic migraine, commented Marc Forth, President and Chief Executive Officer of AEON.
• The insights from our Phase 2 study in episodic migraine were well received by regulators and provide an exciting next step to conduct an interim analysis of the ongoing Phase 2 program in chronic migraine with the same primary endpoint we plan to utilize in the proposed Phase 3 trials.
• With data from over 300 participants that have completed the two 12-week treatment cycles, the interim analysis of the Phase 2 study in chronic migraine is statistically powered to show efficacy.
• We are excited to announce the advancement of our migraine program. The dedication and hard work of our clinical and regulatory teams have been essential in bringing us to this point, and we are incredibly thankful for their efforts, commented Marc Forth, President and Chief Executive Officer of AEON.
• We extend our sincere thanks to the patients, caregivers, and investigators who dedicated their time and effort to participate in our Phase 2 study focusing on episodic and chronic migraine.

Industry Context

This announcement comes as the pharmaceutical industry continues to focus on developing new treatments for migraine, a debilitating condition affecting millions worldwide. AEON's alignment with the FDA on its Phase 3 program and the interim analysis of its Phase 2 chronic migraine study position the company as a potential player in this market. The financing also provides the company with the necessary capital to advance its clinical programs.

Comparison to Industry Standards

• The 15.79% interest rate on the convertible notes is relatively high, suggesting that AEON may have had limited options for financing or that the investors perceived a higher risk.
• The requirement for a $30 million qualified financing to trigger automatic conversion of the notes is a common feature in biotech financings, designed to protect investors from dilution.
• The potential for liquidated damages of up to $1.5 million each for failure to register the retained shares from the terminated forward purchase agreements is a significant liability for AEON.
• The FDA alignment on the Phase 3 trial design is a positive development, as it reduces the risk of regulatory hurdles and increases the likelihood of a successful approval.
• The use of a 12-week evaluation period for the primary endpoint in the chronic migraine study is consistent with industry standards for migraine clinical trials.
• The company's patented treatment paradigm involving fewer injections than the current botulinum toxin treatment option for migraine could provide a competitive advantage.

Management Changes

Stakeholder Impact

• Shareholders: The financing provides capital for the company's development programs, but also introduces potential dilution and debt obligations.
• Employees: The financing provides job security and resources for the company's operations.
• Customers: The company's clinical programs aim to develop new treatments for debilitating medical conditions.
• Suppliers: The company's operations will require ongoing relationships with suppliers.
• Creditors: The company has taken on new debt obligations with the convertible notes.

Next Steps

• AEON will issue and sell the initial $5 million convertible note to Daewoong.
• AEON will seek to amend the license agreement with Daewoong to enable the subsequent $10 million closing.
• AEON will appoint a Daewoong designee to its board of directors.
• AEON will seek stockholder approval to remove conversion caps on the notes.
• AEON will file a shelf registration statement to register the resale of shares issuable upon conversion of the notes.
• AEON will conduct an interim analysis of the ongoing Phase 2 study in chronic migraine and release the data in Q2 2024.
• AEON will advance its ABP-450 program into the proposed pivotal Phase 3 program.

Key Dates

Keywords

AEON Biopharma, Daewoong Pharmaceutical, convertible notes, financing, ABP-450, migraine, clinical trials, FDA, prabotulinumtoxinA, forward purchase agreement